PTO/SB/68 (04-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of	
Application Number: 09/256,388	Filed: 2/24/99
Art Unit	Examiner

Paper No. #8

Assistant Commissioner for Patents
Washington, DC 20231

1. ☑ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line_____,

United States Patent Number 6177077 B1, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which designates the United States, WIPO Pub. No. _____, page _____, line_ ____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or 1.14(e)(2)(i), i.e., Application No._____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Patricia A. Fellenz
Signature

4/30/02
Date

Patricia A Fellenz
Typed or printed name

FOR PTO USE ONLY

Approved by: DW (initials)

Unit: 2811

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

US006177077B1

(12) **United States Patent**
Tobinick

(10) **Patent No.: US 6,177,077 B1**
(45) **Date of Patent: *Jan. 23, 2001**

(54) **TNT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS**

(76) Inventor: **Edward L. Tobinick**, 100 UCLA Medical Plaza, Suite 205, Los Angeles, CA (US) 90024-6903

(*) Notice: Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/476,643**

(22) Filed: **Dec. 31, 1999**

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/275,070, filed on Mar. 23, 1999, now Pat. No. 6,015,557, which is a continuation-in-part of application No. 09/256,388, filed on Feb. 24, 1999, now abandoned.

(51) **Int. Cl.**[7] **A61K 39/395**
(52) **U.S. Cl.** **424/134.1**
(58) **Field of Search** 424/134.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,574,022	11/1996	Roberts et al. .	
5,605,690	2/1997	Jacobs et al. .	
5,650,396	7/1997	Carlino et al. .	
5,656,271	8/1997	Le et al. .	
5,756,482	5/1998	Roberts et al. .	
5,962,481 *	10/1999	Levin et al.	514/352

* cited by examiner

Primary Examiner—William R. A. Jarvis
(74) *Attorney, Agent, or Firm*—Ezra Sutton

(57) **ABSTRACT**

A method is disclosed for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue or the neuromuscular junction of a human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), other agents containing soluble TNF receptors, CDP571 (a humanized monoclonal anti-TNF-alpha antibody), other monoclonal anti-TNF-alpha antibodies, TNF-alpha converting enzyme inhibitors and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue or the neuromuscular junction of a human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of a human.

29 Claims, No Drawings